

## Location

Maison de la Chimie  
28, rue Saint Dominique  
75007 PARIS  
France  
Phone: (+33)1 40 62 27 00



## Registration

Registration required before 20<sup>th</sup> April 2017

### Contact:

Send an email to Isabelle Paty  
[isabelle.paty@ipsen.com](mailto:isabelle.paty@ipsen.com)

**Limited places**

**Cost** (without accommodation)

Club Phase I member price: 150 €


Non member price: 200 €

## Access

RER: Line C, Invalides Station

Subway: Lines 8, 12 et 13, Assemblée  
Nationale, Solférino or Invalides Stations

Bus: Lines 63, 69, 83, 93 et 94



## Closest hotels

Saint Dominique Hotel  
62, rue Saint Dominique

Best Western Tour Eiffel Invalides  
35, boulevard de la Tour Maubourg

Hôtel de Varenne  
44, rue de Bourgogne

Booking directly with the hotel



*Association des professionnels du  
développement précoce du médicament*

&



*Experts in drug development early phase and  
pharmacometrics\**

Present

A New Workshop

Physiologically Based  
Pharmacokinetic modeling (PBPK):  
A new Paradigm in Drug  
Development

April 27<sup>th</sup> 2017

Paris

\* Supported by



## Program

**09:30am** Welcome

**10:00am** Introduction: Physiologically Based Pharmacokinetic principles

→ **Virginie Gualano**, Director and Pharmacometrician, PhinC Development

**10:15am** GastroPlus™ Software general presentation and presentation of the specific modules: Transdermal, nasal pulmonary, oral cavity drug delivery, ocular, Biologic module

→ **John Dibella**, Vice president, Simulations Plus

### 10:45am Break

**11:00am** PBPK, a Platform for Bridging People & Knowledge in Early Drug Development

→ **Neil Miller**, DMPK Investigator and PBPK Leader, GSK

**11:45pm** A comparison of liver models for drug-drug interaction predictions: From static to mechanistic models

→ **Mohammed H. Cherkaoui**, PKPD Translational Medicine Scientist, Medicines for Malaria Venture

**12:15am** Application/study case: Use of combined in vitro, in silico (GastroPlus™) and in vivo (dog) models to anticipate PK behavior of different prototypes of a given compound in human.

→ **Sylvaine Galieue**, Pharmacokineticist, Sanofi

### 12:45am-02:15pm Lunch Break

**02:15pm** Application/study case: FIM preparation: use of PBPK modeling to select the dose schedule and early static DDI assessment

→ **Florent Mazuir**, Pharmacokineticist, Sanofi

**02:45pm** PBPK modelling to derisk DDI: a case study at UCB

→ **François Bouzom**, Director DMPK strategic group, UCB

### 03:30pm Break

**03:45pm** PBPK to guide dose selection in early development and meet regulatory requirements

→ **Thierry Lavé**, Head Project Leader/Modelling & Simulation Pharmaceutical Sciences, Roche

**04:30pm** Guidelines presentation and feedback on regulatory review\*

→ **Ridha Belaiba\***, Pharmacokinetics reviewer at ANSM and member of the Pharmacokinetics Working Party (PKWP) at EMA

\*To be confirmed

**05:15pm-05:30pm** Conclusion